tTF-NGR and Trabectedin Sequencing for Soft-Tissue Sarcoma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for soft-tissue sarcoma, such as Trabectedin, have limited efficacy and are prone to systemic side effects, and there is a need for new therapeutic targets and agents to improve survival rates and reduce toxicity.

Innovation Solution

The combination of Trabectedin with a tTF-NGR protein, which targets tumor vasculature, is administered sequentially to enhance antitumor activity through vascular occlusion and pro-coagulatory effects, potentially achieving synergistic therapeutic benefits.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Trabectedin is administered alone, then antitumor activity is achieved, but therapeutic efficacy is limited and systemic side effects occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidsystemic side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The treatment approach is segmented into two distinct components: Trabectedin for systemic antitumor activity and tTF-NGR for localized vascular targeting. This segmentation allows each agent to perform its specific function while minimizing overlapping toxicities and maximizing synergistic effects.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

tTF-NGR acts as an intermediary that delivers pro-coagulatory activity specifically to the tumor vasculature. This intermediary mechanism creates localized thrombosis that traps Trabectedin in the tumor, enhancing its efficacy while reducing systemic exposure and side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Duration of action of moving object

If conventional chemotherapy is used, then tumor growth is inhibited, but progression-free survival time is only prolonged limitedly

Engineering Contradiction:

Improveprogression-free survival timeVSAvoidtherapeutic effectiveness

Core Design Contradiction:

Duration of action of moving objectVSProductivity

Solution Approach 1:

tTF-NGR is administered to induce vascular occlusion and trap Trabectedin in the tumor before the chemotherapy agent reaches peak systemic concentration. This preliminary action creates a reservoir effect that prolongs intratumoral drug accumulation and extends progression-free survival.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention changes the pharmacokinetic parameters of Trabectedin by modifying its distribution pattern through vascular occlusion. This transforms the drug's behavior from systemic circulation to localized intratumoral accumulation, thereby extending its effective duration of action.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If anti-angiogenic therapy is applied, then vessel formation is interfered with, but therapeutic activity is limited to few months and resistance occurs

Engineering Contradiction:

Improvetherapeutic activity durationVSAvoidresistance development

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

Instead of preventing vessel formation (anti-angiogenic approach), the invention inverts the strategy by targeting existing vessels for occlusion (anti-vascular approach). This inversion destroys the tumor vasculature that has already formed, preventing resistance development through a fundamentally different mechanism.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The invention converts the tumor's own vasculature, which is necessary for its growth, into a therapeutic target. By inducing thrombosis in these vessels, the harmful vascular network becomes the mechanism for delivering therapeutic benefit through localized drug trapping.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of Trabectedin and tTF-NGR shows enhanced antitumor activity by prolonging intratumoral accumulation of Trabectedin and increasing pro-coagulatory effects, leading to improved tumor regression and prolonged progression-free survival without significant systemic toxicity.

Implementation Method 1

tTF-NGR specifically targets the tumor vasculature and induces vascular occlusion and infarction

Methodology Applied

Scientific EffectVascular occlusion: Coagulation

Implementation Method 2

The NGR peptide sequence at the C-terminus of tTF specifically binds to aminopeptidase N (APN, also known as CD13)

Methodology Applied

Scientific EffectPeptide-receptor binding: Adsorption

Implementation Method 3

The vascular tumor occlusion by tTF-NGR prolongs intratumoral accumulation of Trabectedin which results in higher antitumor efficacy

Methodology Applied

Scientific EffectIntratumoral accumulation: Absorption (physical)

Implementation Method 4

a higher intratumoral pro-coagulatory activity of tTF-NGR can be caused by induction of early apoptosis in tumor cells and tumor endothelial cells by Trabectedin with resulting higher phosphatidylserine (PS) levels on these cells

Methodology Applied

Scientific EffectApoptosis:

Data Source

PatentUS12533399B2Composition comprising tTF-NGR for use in treating soft-tissue sarcoma

Publication Date: 2026.01.27 ANTUREC PHARMACEUTICALS GMBH

AI summary

The present invention provides compositions comprising Trabectedin or a tTF-NGR protein for use in the treatment of cancer in an individual, wherein the treatment comprises the following steps: (a) administering to the individual an effective amount of a composition comprising Trabectedin, and (b) subsequently administering to the individual an effective amount of a composition comprising a tTF-NGR protein.